ANIP
ANI Pharmaceuticals, Inc.
Set alert
72.00 USD -1.16 -1.59%
71.90 Day range 73.54
70.16 52-week range 94.48
- YTD
- -8.79%
- 1 year
- -21.68%
- Open
- 73.27
- Prev close
- 73.16
- Mkt cap
- 1.65B
- Vol
- 286.90K
- Avg vol
- 386.56K
- EPS
- 4.62
- P/E
- 15.58
- Div yield
- 0.00%
More statistics
- Low
- 71.90
- High
- 73.54
- Forward P/E
- 7.14
- Beta
- 0.49
- Short ratio
- 8.21
- Inst. own
- 107.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 73.06
- 200-d avg
- 77.72
- 1y target
- 105.78
Financial health
Altman Z-Score
2.62 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
7 / 9 Strong
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 1
- Return on Equity 4
- Return on Assets 4
- Debt / Equity 2
- P/E 3
- P/B 2
Valuation
P/E 22.6×
FY 2016 5y median -13.2× FY 2025
P/S 1.8×
FY 2016 5y median 2.0× FY 2025
P/B 2.9×
FY 2016 5y median 2.2× FY 2025
P/FCF 10.5×
FY 2016 5y median 9.9× FY 2025
EV/EBITDA 7.8×
FY 2016 5y median 24.5× FY 2025
EV/Sales 1.8×
FY 2016 5y median 2.5× FY 2025
FCF Yield 9.5%
FY 2016 5y median 4.4% FY 2025
Profitability
Gross Margin 51.0%
FY 2016 5y median 56.1% FY 2025
Operating Margin 9.2%
FY 2016 5y median 0.1% FY 2025
Net Margin 8.9%
FY 2016 5y median -3.0% FY 2025
ROE 14.5%
FY 2016 5y median -4.3% FY 2025
ROIC 5.6%
FY 2016 5y median 0.0% FY 2025
ROA 5.4%
FY 2016 5y median -1.4% FY 2025
Growth (YoY)
Revenue 43.8%
FY 2016 FY 2025
Operating Income 13809.2%
FY 2016 FY 2025
EPS (diluted) 419.2%
FY 2016 FY 2025
Free Cash Flow 220.6%
FY 2016 FY 2025
Financial Health
Current Ratio 2.7×
FY 2016 5y median 3.5× FY 2025
Quick Ratio 2.2×
FY 2016 5y median 2.4× FY 2025
Debt / Equity 0.6×
FY 2016 5y median 0.8× FY 2025
Net Debt / EBITDA 0.2×
FY 2016 5y median 7.6× FY 2025
Interest Coverage 4.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.1%
FY 2016 5y median 0.2% FY 2025
Payout Ratio 1.5%
FY 2016 5y median -0.4% FY 2025
Annual · latest fiscal year ends 2025-12-31